GUT-resident macrophage regulation of gastric dysmotility and barrier dysfunction in gastroparesis

Active Grant Awarded

Award ID
R01DK148906
Recipient
Awarding agency
Obligated
$642,756

Award facts

Completion date 4% complete
Place of performance
Reno, NV 89557, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases awarded Board of Regents of Nevada System of Higher Education, doing business as University of Nevada, Reno, $642,756 under Grant R01DK148906 on September 9, 2026. The award is funded under Assistance Listing 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research, a program supporting extramural basic and clinical biomedical research on diabetes, digestive, and kidney diseases.

The project tests a macrophage-centric model of gastroparesis, examining gut-resident macrophages in the mucosa and muscularis as drivers of impaired barrier integrity and gastric dysmotility. The work combines multi-omics profiling (scRNA-seq, miRNA-seq, CyTOF) with mechanistic and functional analysis, and it evaluates a therapeutic strategy centered on the miR-10b-5p, KLF7, and IL-6 axis. The study hypothesizes that miR-10b-5p deficiency skews gut-resident macrophages toward pro-inflammatory states through KLF7, elevating IL-6 and disrupting motility and barrier function.

The period of performance runs from September 9, 2026 to an ultimate completion date of June 30, 2031. Work is performed in Reno, Nevada 89557.

Description

Abstract
Gastroparesis is a debilitating gastrointestinal disorder marked by delayed gastric emptying without mechanical obstruction, affecting up to 4% of the U.S. Population, with high symptom burden, healthcare utilization, and reduced quality of life. No disease-modifying therapy exists. The proposed research will directly test a macrophage-centric model of gastroparesis, an understudied gastric neuromuscular condition. We propose a cohesive framework that integrates discovery through multi-omics profiling (scrna-SEQ, mirna-SEQ, cytof), mechanistic insight, functional analysis, and therapeutic innovation centered on the MIR-10B-KLF7-IL-6 axis. Despite gastroparesis causing pan-enteric dysmotility, immune dysregulation, and barrier dysfunction, the cellular and molecular mechanisms underlying these conditions remain poorly defined. This study addresses a critical GAP by establishing GUT-resident macrophages, including those in the mucosa and muscularis, as drivers of impaired barrier integrity and gastric dysmotility. While functional dyspepsia (FD) and gastroparesis overlap clinically, our focus is on gastroparesis; we leverage duodenal mucosal readouts as upstream signals that propagate to gastric neuromuscular outcomes. Beyond gastroparesis, the findings could unlock therapeutic strategies for a wide range of GUT-brain interaction disorders and barrier dysfunction syndromes. By targeting a host epigenetic regulator (MIR-10B-5P) to suppress KLF7-driven IL-6 signaling and reprogram macrophage states, we advance a first-in-field, mechanism-anchored therapeutic strategy for gastroparesis. We hypothesize that MIR-10B-5P deficiency skews GUT-resident macrophages toward pro-inflammatory states via KLF7, thereby elevating IL-6 and disrupting motility and barrier function. This model is supported by preliminary data in mice and humans, as well as functional rescue with a MIR-10B mimic. Using macrophage- specific transgenic models (CX3CR1-MIR-10B KO, tdtomato reporter, depletion lines) integrated with human biopsies, we propose three aims: (1) determine how MIR-10B loss disrupts muscularis macrophages and dysmotility using scrna-SEQ and gastric emptying assays; (2) define the mucosal macrophage control of barrier integrity via ussing chamber/teer measurements and scrna-SEQ/cytof; (3) test a macrophage- reprogramming intervention with MIR-10B-5P mimics to reverse pathologies. Human gastric and duodenal biopsies (musc collaboration) will anchor translational relevance, with scrna-SEQ and cytof linking cellular states to clinical phenotypes and defining biomarker readouts (MIR-10B/KLF7/IL-6, ZO-1) for future trials. Our methodology is robust and meticulously designed, incorporating hypothesis-driven experiments, pre- specified inclusion/exclusion criteria, randomization/blinding, and contingency plans to ensure reliable, reproducible results. Supported by our multidisciplinary team and strong institutional infrastructure, this research is positioned to deliver breakthrough insights and a mechanism-based therapeutic path for gastroparesis patients in urgent need.

Quick answers

Who received award R01DK148906?

R01DK148906 was awarded to Board Of Regents Of Nevada System Of Higher Education by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 9, 2026.

How much is award R01DK148906 worth?

$642,756 has been obligated on R01DK148906.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award